Biocon Partners With Voluntis On Digital Therapeutics For Diabetics
Insulia Digital Tool To Be Paired With Biocon Insulins
Executive Summary
The global collaboration agreement pairs Biocon’s insulins with Voluntis’s Insulia, the first digital therapeutic with regulatory clearance for insulin-dependent type 2 diabetes patients. Biocon further reveals plans for a complete digital therapeutics portfolio for patients
You may also be interested in...
Asia Deal Watch: Perceptive Launches LianBio With “China-Centric” Strategy
Headquartered in both China and US, the new firm will help partners bring drugs to China and other Asian markets. Novavax licenses COVID-19 vaccine in Japan to Takeda, following previous week’s deal for the vaccine in India.
Biocon Sees Recovery In Biosimilars
Biocon’s biosimilars business sees bounce-back in first quarter of fiscal 2021, with the US business witnessing gradually improving demand. The Indian company also sees potential for improved affordability in the US.
Biocon Sees Recovery In Biosimilars, Scope To Address Affordability In US
Biocon’s biosimilars business sees bounce-back in first quarter of fiscal 2021, with the US business witnessing gradually improving demand. The Indian company also sees potential for improved affordability in the US.